Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Ethical Drug Sales Up 2.0% in October: Crecon
December 13, 2018
- Otsuka’s US Subsidiary Pulls Plug on License Deal to Sumatriptan Nasal Spray for Acute Migraine
December 13, 2018
- Eisai, Takeda to Provide Compound Libraries to GARDP for Development of New Antibiotics
December 13, 2018
- Armed with 2 New Drugs, EA Pharma Looks to Raise Profile in Chronic Constipation Space
December 12, 2018
- Astellas FLT3 Inhibitor Xospata Now Available in US
December 12, 2018
- Daiichi Sankyo, Sarah Cannon Ink Cancer Collaboration, DS-7300 Trial to Get Underway in FY2019
December 12, 2018
- Ribomic Hooks Up with US Research Consortium on FGF Aptamer Therapeutics
December 12, 2018
- Mitsubishi Tanabe Links Up with Chinese Biopharma to Streamline Search for Seed Compounds
December 12, 2018
- DS-8201 Yields 44.2% ORR in HER2-Low Breast Cancer: Daiichi Sankyo
December 11, 2018
- Avastin Top-Seller Drug in Japan for 4 Months Running: Encise Snapshot
December 11, 2018
- Pfizer Marks Foray into Japan Biosimilar Market with Remicade Follow-On
December 11, 2018
- Mitsubishi Tanabe Begins Study to Identify ALS Biomarkers
December 11, 2018
- Shionogi, Ube Join Hands on Respiratory Syncytial Virus Research
December 11, 2018
- Daiichi Sankyo Grabs Top Spot in Combined Approach of Sales Reps’ Visits, e-Detailing: Survey
December 11, 2018
- Roche Diagnostics Files PD-L1 Test Kit for Imfinzi in Japan
December 10, 2018
- Tecentriq Filed in Japan for 1st Line SCLC: Chugai
December 10, 2018
- RaQualia Launches New Subsidiary for Commercialization of New Projects
December 10, 2018
- Pfizer Files Rheumatrex for Psoriasis Based on Information in Public Domain
December 10, 2018
- Chugai’s Tecentriq Gets Orphan Status in SCLC, Entrectinib in NTRK-Mutated Solid Tumors
December 7, 2018
- Shionogi Set to Get Its Hands on Vast’s Nitric Oxide-Releasing Antimicrobial Agent
December 7, 2018
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…